AAPL324.53-0.61 (-0.19%) ▼|ABBV258.72-1.27 (-0.49%) ▼|ABT112.09+3.16 (+2.90%) ▲|ACN186.16-1.93 (-1.03%) ▼|ADBE282.68-3.41 (-1.19%) ▼|AMAT437.13-4.73 (-1.07%) ▼|AMD457.95-1.66 (-0.36%) ▼|AMGN437.01-1.11 (-0.25%) ▼|AMT174.30-1.72 (-0.98%) ▼|AMZN255.10+0.18 (+0.07%) ▲|AVGO369.77+0.09 (+0.02%) ▲|AXP329.95+5.76 (+1.78%) ▲|BA210.00+4.34 (+2.11%) ▲|BAC63.18+1.19 (+1.91%) ▲|BKNG198.67+2.98 (+1.52%) ▲|BLK1,123.43-4.67 (-0.41%) ▼|BMY67.06+0.14 (+0.21%) ▲|BNY161.84+1.33 (+0.83%) ▲|BRK-B507.73+5.40 (+1.08%) ▲|C134.93+2.39 (+1.80%) ▲|CAT785.34+6.18 (+0.79%) ▲|CL90.45+0.82 (+0.91%) ▲|CMCSA27.06+0.76 (+2.89%) ▲|COF218.64+7.30 (+3.45%) ▲|COP136.28+0.09 (+0.07%) ▲|COST934.82-5.14 (-0.55%) ▼|CRM255.33-2.79 (-1.08%) ▼|CSCO109.01-0.73 (-0.67%) ▼|CVS98.41+0.81 (+0.83%) ▲|CVX211.71+0.66 (+0.31%) ▲|DE686.10+10.02 (+1.48%) ▲|DHR210.09+3.16 (+1.52%) ▲|DIS108.68+2.46 (+2.31%) ▲|DUK120.34-0.05 (-0.04%) ▼|EMR149.61+1.98 (+1.34%) ▲|FDX322.30-2.58 (-0.79%) ▼|GD363.41-6.01 (-1.63%) ▼|GE332.17+1.08 (+0.33%) ▲|GEV901.08+2.55 (+0.28%) ▲|GILD150.10+0.18 (+0.12%) ▲|GM85.09-0.54 (-0.63%) ▼|GOOG333.66+1.63 (+0.49%) ▲|GOOGL337.29+2.27 (+0.68%) ▲|GS1,007.58+5.02 (+0.50%) ▲|HD320.31+0.54 (+0.17%) ▲|HON208.39-1.59 (-0.76%) ▼|IBM230.57-0.83 (-0.36%) ▼|INTC89.54+0.57 (+0.64%) ▲|INTU343.17-1.77 (-0.51%) ▼|ISRG380.16+10.91 (+2.95%) ▲|JNJ274.41+3.22 (+1.19%) ▲|JPM358.82+3.87 (+1.09%) ▲|KO88.78+0.78 (+0.89%) ▲|LIN488.69+1.93 (+0.40%) ▲|LLY1,174.01+14.01 (+1.21%) ▲|LMT533.01-11.50 (-2.11%) ▼|LOW201.48+1.43 (+0.71%) ▲|LRCX287.10-3.10 (-1.07%) ▼|MA589.42+8.32 (+1.43%) ▲|MCD262.52+1.41 (+0.54%) ▲|MDLZ62.37+0.76 (+1.23%) ▲|MDT94.26+2.22 (+2.41%) ▲|META595.84+17.30 (+2.99%) ▲|MMM169.96-0.28 (-0.17%) ▼|MO69.49-0.08 (-0.12%) ▼|MRK150.63+0.77 (+0.51%) ▲|MS213.63+2.59 (+1.23%) ▲|MSFT497.62-3.40 (-0.68%) ▼|MU940.77+7.33 (+0.78%) ▲|NEE82.77-0.16 (-0.19%) ▼|NFLX82.68+1.87 (+2.31%) ▲|NKE38.48+0.36 (+0.94%) ▲|NOW138.12-4.78 (-3.35%) ▼|NVDA226.23+8.79 (+4.04%) ▲|ORCL145.44+4.12 (+2.92%) ▲|PEP141.48+1.69 (+1.21%) ▲|PFE28.86+0.31 (+1.07%) ▲|PG147.58+1.37 (+0.94%) ▲|PLTR170.04-9.88 (-5.49%) ▼|PM188.16+1.01 (+0.54%) ▲|QCOM169.42+2.81 (+1.69%) ▲|RTX202.29-2.87 (-1.40%) ▼|SBUX107.60+1.45 (+1.37%) ▲|SCHW109.43+1.15 (+1.06%) ▲|SO88.02-0.07 (-0.08%) ▼|SPG210.21-1.66 (-0.78%) ▼|T26.36+0.36 (+1.37%) ▲|TMO607.30+6.80 (+1.13%) ▲|TMUS187.48+5.32 (+2.92%) ▲|TSLA355.30-0.79 (-0.22%) ▼|TXN256.70+3.36 (+1.32%) ▲|UBER76.60+1.36 (+1.80%) ▲|UNH400.09+3.79 (+0.96%) ▲|UNP290.67+0.05 (+0.02%) ▲|UPS103.26+0.60 (+0.58%) ▲|USB62.60+1.39 (+2.26%) ▲|V379.26+6.59 (+1.77%) ▲|VZ50.69+0.39 (+0.77%) ▲|WFC89.67+2.63 (+3.02%) ▲|WMT106.05+0.13 (+0.12%) ▲|XOM163.07-1.49 (-0.90%) ▼|AAPL324.53-0.61 (-0.19%) ▼|ABBV258.72-1.27 (-0.49%) ▼|ABT112.09+3.16 (+2.90%) ▲|ACN186.16-1.93 (-1.03%) ▼|ADBE282.68-3.41 (-1.19%) ▼|AMAT437.13-4.73 (-1.07%) ▼|AMD457.95-1.66 (-0.36%) ▼|AMGN437.01-1.11 (-0.25%) ▼|AMT174.30-1.72 (-0.98%) ▼|AMZN255.10+0.18 (+0.07%) ▲|AVGO369.77+0.09 (+0.02%) ▲|AXP329.95+5.76 (+1.78%) ▲|BA210.00+4.34 (+2.11%) ▲|BAC63.18+1.19 (+1.91%) ▲|BKNG198.67+2.98 (+1.52%) ▲|BLK1,123.43-4.67 (-0.41%) ▼|BMY67.06+0.14 (+0.21%) ▲|BNY161.84+1.33 (+0.83%) ▲|BRK-B507.73+5.40 (+1.08%) ▲|C134.93+2.39 (+1.80%) ▲|CAT785.34+6.18 (+0.79%) ▲|CL90.45+0.82 (+0.91%) ▲|CMCSA27.06+0.76 (+2.89%) ▲|COF218.64+7.30 (+3.45%) ▲|COP136.28+0.09 (+0.07%) ▲|COST934.82-5.14 (-0.55%) ▼|CRM255.33-2.79 (-1.08%) ▼|CSCO109.01-0.73 (-0.67%) ▼|CVS98.41+0.81 (+0.83%) ▲|CVX211.71+0.66 (+0.31%) ▲|DE686.10+10.02 (+1.48%) ▲|DHR210.09+3.16 (+1.52%) ▲|DIS108.68+2.46 (+2.31%) ▲|DUK120.34-0.05 (-0.04%) ▼|EMR149.61+1.98 (+1.34%) ▲|FDX322.30-2.58 (-0.79%) ▼|GD363.41-6.01 (-1.63%) ▼|GE332.17+1.08 (+0.33%) ▲|GEV901.08+2.55 (+0.28%) ▲|GILD150.10+0.18 (+0.12%) ▲|GM85.09-0.54 (-0.63%) ▼|GOOG333.66+1.63 (+0.49%) ▲|GOOGL337.29+2.27 (+0.68%) ▲|GS1,007.58+5.02 (+0.50%) ▲|HD320.31+0.54 (+0.17%) ▲|HON208.39-1.59 (-0.76%) ▼|IBM230.57-0.83 (-0.36%) ▼|INTC89.54+0.57 (+0.64%) ▲|INTU343.17-1.77 (-0.51%) ▼|ISRG380.16+10.91 (+2.95%) ▲|JNJ274.41+3.22 (+1.19%) ▲|JPM358.82+3.87 (+1.09%) ▲|KO88.78+0.78 (+0.89%) ▲|LIN488.69+1.93 (+0.40%) ▲|LLY1,174.01+14.01 (+1.21%) ▲|LMT533.01-11.50 (-2.11%) ▼|LOW201.48+1.43 (+0.71%) ▲|LRCX287.10-3.10 (-1.07%) ▼|MA589.42+8.32 (+1.43%) ▲|MCD262.52+1.41 (+0.54%) ▲|MDLZ62.37+0.76 (+1.23%) ▲|MDT94.26+2.22 (+2.41%) ▲|META595.84+17.30 (+2.99%) ▲|MMM169.96-0.28 (-0.17%) ▼|MO69.49-0.08 (-0.12%) ▼|MRK150.63+0.77 (+0.51%) ▲|MS213.63+2.59 (+1.23%) ▲|MSFT497.62-3.40 (-0.68%) ▼|MU940.77+7.33 (+0.78%) ▲|NEE82.77-0.16 (-0.19%) ▼|NFLX82.68+1.87 (+2.31%) ▲|NKE38.48+0.36 (+0.94%) ▲|NOW138.12-4.78 (-3.35%) ▼|NVDA226.23+8.79 (+4.04%) ▲|ORCL145.44+4.12 (+2.92%) ▲|PEP141.48+1.69 (+1.21%) ▲|PFE28.86+0.31 (+1.07%) ▲|PG147.58+1.37 (+0.94%) ▲|PLTR170.04-9.88 (-5.49%) ▼|PM188.16+1.01 (+0.54%) ▲|QCOM169.42+2.81 (+1.69%) ▲|RTX202.29-2.87 (-1.40%) ▼|SBUX107.60+1.45 (+1.37%) ▲|SCHW109.43+1.15 (+1.06%) ▲|SO88.02-0.07 (-0.08%) ▼|SPG210.21-1.66 (-0.78%) ▼|T26.36+0.36 (+1.37%) ▲|TMO607.30+6.80 (+1.13%) ▲|TMUS187.48+5.32 (+2.92%) ▲|TSLA355.30-0.79 (-0.22%) ▼|TXN256.70+3.36 (+1.32%) ▲|UBER76.60+1.36 (+1.80%) ▲|UNH400.09+3.79 (+0.96%) ▲|UNP290.67+0.05 (+0.02%) ▲|UPS103.26+0.60 (+0.58%) ▲|USB62.60+1.39 (+2.26%) ▲|V379.26+6.59 (+1.77%) ▲|VZ50.69+0.39 (+0.77%) ▲|WFC89.67+2.63 (+3.02%) ▲|WMT106.05+0.13 (+0.12%) ▲|XOM163.07-1.49 (-0.90%) ▼|
21.3 C
New York
Wednesday, September 2, 2026

Tag: care

newssourceFORcompanyinformationcontent1releasesmarket

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast, Bharuch district, GujaratEmployees and communities work together to conserve...

Leading Vision Insurance for Glasses (2026): VSP Individual Vision Plans Named Top Plan for Frames and Lens Coverage by Better Business Advice

NEW YORK, June 6, 2026 /PRNewswire/ -- VSP® Individual Vision Plans has been recognized by Better Business Advice as a top vision insurance option...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Global Rise in Delayed Childbearing and Infertility Drives Demand for Cross-Border Fertility Care

Asian Case Studies Highlight How Regulation, Cost, and Access Are Shaping International Family ChoicesTAIPEI, June 6, 2026 /PRNewswire/ -- Delayed marriage, postponed childbearing, and...

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney diseaseZHUBEI CITY, Taiwan and RALEIGH, N.C.,...

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

Wage gains, retiree benefits highlight Port Colborne Steelworkers’ contract at Vale

Port Colborne Steelworkers secure major wage gains and restore retiree health-care benefits.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCare

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers